Gene therapy (AAV vector) · Gene replacement · developed by MeiraGTx UK II
AAV-CNGB3 is an adeno-associated viral vector gene therapy carrying the CNGB3 gene, which encodes the beta subunit of the cone photoreceptor cyclic nucleotide-gated channel. It is being studied in achromatopsia, an inherited condition of impaired cone function and color vision.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03001310 | Phase 1/2 | Achromatopsia | Completed | MGTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Achromatopsia
Updated Oct 25, 2026. Something wrong or missing? Report it on the MGTX page.
See MGTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MGTX catalysts and pipeline →